for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Haemonetics Corporation

HAE

Latest Trade

53.64USD

Change

0.00(0.00%)

Volume

614,996

Today's Range

50.15

 - 

53.65

52 Week Range

49.26

 - 

142.11

As of on the New York Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
53.64
Open
50.15
Volume
614,996
3M AVG Volume
9.71
Today's High
53.65
Today's Low
50.15
52 Week High
142.11
52 Week Low
49.26
Shares Out (MIL)
51.11
Market Cap (MIL)
2,563.44
Forward P/E
19.85
Dividend (Yield %)
--

Next Event

Q3 2022 Haemonetics Corp Earnings Release

Latest Developments

More

Haemonetics Says VASCADE MVP Venous Vascular Closure System Gains First And Only FDA Approval For Same-Day Discharge Following Atrial Fibrillation Ablation

Haemonetics Corp's Q1 Fiscal 2022 Revenue Was $228.5 Mln, Up 16.8%

Haemonetics Reports Q4 Loss Per Share Of $0.22

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Haemonetics Corporation

Haemonetics Corporation (Haemonetics) is a healthcare company. The Company provides a suite of medical products and solutions for customers, to help them improve patient care and reduce the cost of healthcare. Its technology addresses medical markets: blood and plasma component collection, the surgical suite and hospital transfusion services. Its segments include Plasma, Blood Center and Hospital. Its Plasma segment offers automated plasma collection and donor management software systems that improve the donor experience at plasma collection centers. Its Blood Center segment offers a range of solutions that improve donor collection centers' ability to acquire blood, filter blood and separate blood components. Its Hospital segment provides the patient care. It markets and sells its products to biopharmaceutical companies, blood collection groups and independent blood centers, hospitals and hospital service providers, group purchasing organizations and national health organizations.

Industry

Medical Equipment & Supplies

Contact Info

125 SUMMER STREET

BOSTON, MA

02110

United States

+1.781.8487100

https://www.haemonetics.com

Executive Leadership

Ellen M. Zane

Independent Chairman of the Board

Christopher A. Simon

President, Chief Executive Officer, Director

William P. Burke

Chief Financial Officer, Executive Vice President

Anila Lingamneni

Executive Vice President, Chief Technology Officer

Michelle L. Basil

Executive Vice President, General Counsel

Key Stats

1.75 mean rating - 8 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2019

1.0K

2020

1.0K

2021

0.9K

2022(E)

1.0K
EPS (USD)

2019

2.390

2020

3.310

2021

2.350

2022(E)

2.527
Price To Earnings (TTM)
82.93
Price To Sales (TTM)
2.75
Price To Book (MRQ)
3.67
Price To Cash Flow (TTM)
20.93
Total Debt To Equity (MRQ)
111.77
LT Debt To Equity (MRQ)
99.93
Return on Investment (TTM)
2.41
Return on Equity (TTM)
1.94

Latest News

Latest News

BRIEF-Haemonetics CEO Christopher Simon's 2020 Total Compensation Was $9.4 Mln Vls $8.6 Million In 2019

* HAEMONETICS SAYS CEO CHRISTOPHER A. SIMON’S FY 2020 TOTAL COMPENSATION WAS $9.4 MILLION VERSUS $8.6 MILLION IN FY 2019 - SEC FILING

BRIEF-Haemonetics Reports Blood Filter Supply Agreement, Sale Of Puerto Rico-Based Operations To GVS

* HAEMONETICS ANNOUNCES BLOOD FILTER SUPPLY AGREEMENT AND SALE OF PUERTO RICO-BASED MANUFACTURING OPERATIONS TO GVS, S.P.A

BRIEF-Haemonetics Says GPI Will Pay Co $14 Mln In Upfront Cash At Closing Of Asset Transfer

* HAEMONETICS - UNDER TERMS OF ASSET PURCHASE AGREEMENT WITH GPI GROUP, GPI WILL PAY CO $14 MILLION IN UPFRONT CASH AT CLOSING OF ASSET TRANSFER Source: (https://bit.ly/3guMosZ) Further company coverage:

BRIEF-Haemonetics Announces Sale Of U.S. Blood Donor Management Software Solution Assets To The GPI Group

* HAEMONETICS ANNOUNCES SALE OF U.S. BLOOD DONOR MANAGEMENT SOFTWARE SOLUTION ASSETS TO THE GPI GROUP

BRIEF-GPI SpA To Acquire Haemonetics’ U.S. Blood Donor Software Assets

* GPI S.P.A. - BLOOD MANAGEMENT, GPI TO ACQUIRE HAEMONETICS’ U.S. BLOOD DONOR SOFTWARE ASSETS

BRIEF-Haemonetics Reports Q4 Adjusted Earnings Per Share $0.69

* Q4 EARNINGS PER SHARE VIEW $0.73, REVENUE VIEW $246.5 MILLION -- REFINITIV IBES DATA

BRIEF-Haemonetics Acquires Enicor GmbH To Expand Advanced Viscoelastic Testing Portfolio

* HAEMONETICS ACQUIRES ENICOR GMBH TO EXPAND ADVANCED VISCOELASTIC TESTING PORTFOLIO

BRIEF-Haemonetics Appoints Anila Lingamneni Executive Vice President, Chief Technology Officer

* HAEMONETICS APPOINTS ANILA LINGAMNENI EXECUTIVE VICE PRESIDENT, CHIEF TECHNOLOGY OFFICER Source text for Eikon: Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up